Option Care Health Stock (NASDAQ:OPCH)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$21.90

52W Range

$18.01 - $36.80

50D Avg

$21.77

200D Avg

$28.24

Market Cap

$3.35B

Avg Vol (3M)

$3.33M

Beta

0.65

Div Yield

-

OPCH Company Profile


Option Care Health, Inc. delivers infusion services to patients in their homes and other non-hospital settings throughout the United States. The company offers a broad spectrum of specialized infusion treatments, including therapies for various infections, management of heart failure, and comprehensive nutritional support (both intravenous and tube feeding) for individuals with acute or chronic conditions such as stroke, cancer, and digestive illnesses. They also provide immunoglobulin infusions for immune system deficiencies and treatments targeting chronic inflammatory disorders like Crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis. Furthermore, Option Care Health assists in managing the progression of neurological conditions such as amyotrophic lateral sclerosis (ALS) and Duchenne muscular dystrophy. They also administer infusion therapies for bleeding disorders and provide crucial support for women experiencing high-risk pregnancies. Other specialized infusion services encompass pain relief, chemotherapy, and respiratory care. Complementing these medical offerings, the company provides professional nursing services. Option Care Health, Inc. maintains its primary corporate office in Bannockburn, Illinois.

Show More

Industry

Medical - Care Facilities

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

8,000

IPO Date

Aug 15, 1996

Website

OPCH Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 25
Reportable Segment$5.65B

Fiscal year ends in Dec 25 | Currency in USD

OPCH Financial Summary


Dec 25Dec 24Dec 23
Revenue$5.65B$5.00B$4.30B
Operating Income$337.91M$321.83M$314.60M
Net Income$207.59M$211.82M$267.09M
EBITDA$403.70M$396.13M$472.19M
Basic EPS$1.28$1.23$1.49
Diluted EPS$1.28$1.23$1.48

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts


Q1 26Apr 30, 26 | 12:00 AM
Q4 25Feb 24, 26 | 8:30 AM
Q3 25Oct 30, 25 | 8:30 AM

Peer Comparison


TickerCompany
HNGEHinge Health, Inc.
ADMAADMA Biologics, Inc.
OSCROscar Health, Inc.
ACADACADIA Pharmaceuticals Inc.
KYMRKymera Therapeutics, Inc.
TMDXTransMedics Group, Inc.
AKROAkero Therapeutics, Inc.
IMVTImmunovant, Inc.
LNTHLantheus Holdings, Inc.